![]() |
|
|
Vol. 299, Issue 2, 712-717, November 2001
-Imager for Rapid ex Vivo Autoradiography
Exemplified with Central Nervous System Penetrating Neurokinin 3 Antagonists
Department of Receptor Pharmacology, Janssen Research Foundation,
Beerse, Belgium
The neurokinin 3 (NK3) receptor antagonists represent a novel class of
pharmacological agents, which are currently under evaluation for the
treatment of psychiatric disorders. An efficient brain penetration is
one of the main prerequisites to further evaluate compounds displaying
high potency to bind the NK3 receptor. The present report describes a
method for determining the in vivo occupancy of central NK3 receptors
after peripheral administration of drugs. An ex vivo measurement of NK3
receptor occupancy by quantitative autoradiography employing
[3H]senktide as the radioligand has been developed. The
speed of the method, which is usually considered low due to the time
dedicated to film exposure (from weeks to months), has been
considerably increased by the use of the
-imager. The high
sensitivity of this new radioimager was used to visualize and
quantitatively analyze the [3H]senktide binding sites in
brain sections within hours. Using this method, we have
demonstrated that the reference NK3 antagonist SR142801 dose
dependently occupied the NK3 receptors in the gerbil brain after
subcutaneous administration with an ED50 of 0.85 mg/kg. The
less active enantiomer SR142806 occupied the NK3 receptors only by 25%
at the highest used dose of 10 mg/kg. These values are in accordance
with the reported behavioral effects of the compounds. Our results
indicate that ex vivo receptor occupancy measurements can be
dependently used to predict the central activity of NK3 antagonists.
More generally, the combination of ex vivo receptor autoradiography
with the
-imager detection constitutes a new and fast method to
evaluate the brain penetration of drug candidates.
This article has been cited by other articles:
![]() |
C. Dugovic, J. E. Shelton, L. E. Aluisio, I. C. Fraser, X. Jiang, S. W. Sutton, P. Bonaventure, S. Yun, X. Li, B. Lord, et al. Blockade of Orexin-1 Receptors Attenuates Orexin-2 Receptor Antagonism-Induced Sleep Promotion in the Rat J. Pharmacol. Exp. Ther., July 1, 2009; 330(1): 142 - 151. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Hess, R. W. Ransom, Z. Zeng, R. S. L. Chang, P. J. Hey, L. Warren, C. M. Harrell, K. L. Murphy, T.-B. Chen, P. J. Miller, et al. Generation and Characterization of a Human Bradykinin Receptor B1 Transgenic Rat as a Pharmacodynamic Model J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 488 - 497. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Bonaventure, D. Nepomuceno, C. Mazur, B. Lord, D. A. Rudolph, J. A. Jablonowski, N. I. Carruthers, and T. W. Lovenberg Characterization of N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyano-phenyl)-N-[1-(2-cyclopentyl-ethyl)-piperidin-4yl]acrylamide (JNJ-5207787), a Small Molecule Antagonist of the Neuropeptide Y Y2 Receptor J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 1130 - 1137. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-W. Li, G. Hill, H. Wong, N. Kelly, K. Ward, M. Pierdomenico, S. Ren, P. Gilligan, S. Grossman, G. Trainor, et al. Receptor Occupancy of Nonpeptide Corticotropin-Releasing Factor 1 Antagonist DMP696: Correlation with Drug Exposure and Anxiolytic Efficacy J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 86 - 96. [Abstract] [Full Text] [PDF] |
||||